Literature DB >> 8781898

The natural history of chronic hepatitis C infection.

D B Strader1, L B Seeff.   

Abstract

Hepatitis C is among the most common causes of chronic liver disease affecting approximately 1% of the world's population. End-stage hepatitis C virus (HCV)-related chronic liver disease is the leading indication for orthotopic liver transplantation worldwide. Despite these facts, many questions regarding the natural history of HCV infection remain unanswered. Is progression to end-stage liver disease inevitable? Over what time period does it occur? If progression is not inevitable, can we identify those persons destined to have end-stage liver disease and possibly prevent or slow progression?

Entities:  

Mesh：

Year:  1996        PMID： 8781898     DOI： 10.1097/00042737-199604000-00006

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN： 0954-691X            Impact factor:   2.566


  11 in total

1.  Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Authors:  A B Jazwinski; A J Thompson; P J Clark; S Naggie; H L Tillmann; K Patel
Journal:  J Viral Hepat       Date:  2011-11-24       Impact factor: 3.728

Review 2.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection.

Authors:  Mayumi Tokunaga; Hirofumi Uto; Kohei Oda; Masahito Tokunaga; Seiichi Mawatari; Kotaro Kumagai; Kouichi Haraguchi; Makoto Oketani; Akio Ido; Nobuhito Ohnou; Atae Utsunomiya; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2014-01-25       Impact factor: 7.527

4.  Morphine enhances hepatitis C virus (HCV) replicon expression.

Authors:  Yuan Li; Ting Zhang; Steven D Douglas; Jian-Ping Lai; Wei-Dong Xiao; David E Pleasure; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

5.  Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.

Authors:  Col Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2011-08-26

6.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

7.  Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.

Authors:  Sang Bun Choi; Youn Jae Lee; Jae Ik Lee; Young Jin Song; Byoung Jin Choi; Jong Han Kim; Eun Uk Jung; Sung Jae Park; Sang Heon Lee; Ji Hyun Kim; Jung Sik Choi; Sam Ryong Jee; Sang Yong Seol
Journal:  Korean J Hepatol       Date:  2011-09

8.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

9.  SASLT practice guidelines: management of hepatitis C virus infection.

Authors:  Abdullah S Alghamdi; Faisal M Sanai; Mona Ismail; Hamdan Alghamdi; Khalid Alswat; Adel Alqutub; Ibrahim Altraif; Hemant Shah; Faleh Z Alfaleh
Journal:  Saudi J Gastroenterol       Date:  2012-09       Impact factor: 2.485

10.  Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C.

Authors:  Seok Hoo Jeong; Young Kul Jung; Jae Won Yang; Sang Jin Park; Jong Woo Kim; Oh Sang Kwon; Yun Soo Kim; Duck Joo Choi; Ju Hyun Kim
Journal:  Clin Mol Hepatol       Date:  2012-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.